Wockhardt has won FDA approval for four generics products in a matter of days. On 16 August 2012, the India-based company announced the final approval and immediate product launch of the anti-blood clotting drug clopidogrel bisulfate in 75 mg tablet form, and tentative approval for 300 mg-containing tablets.
- Home
 - 
                                Generics 
                                                                
News
- FDA approves generic teriparatide and levetiracetam
 - US generics launch and approval for Dr Reddy’s and Lupin
 - Five Chinese companies join UN’s MPP for Covid-19 medicines
 - South Korean companies to make generic Bridion and COVID-19 drugs
 
Research
- Japan’s drug shortage crisis: challenges and policy solutions
 - Saudi FDA drug approvals and GMP inspections: trend analysis
 - Generic medications in the Lebanese community: understanding and public perception
 - Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
 
 - 
                                Biosimilars 
                                                                
News
- FDA approves six denosumab biosimilars
 - EMA recommends approval for four biosimilars targeting three therapies
 - FDA approves first interchangeable rapid-acting insulin biosimilar, Kirsty
 - ANVISA approves ranibizumab and tocilizumab biosimilars
 
 - MORE EDITORIAL SECTIONS
 
- Search
 
                    


            
    
    
                        
                            
            
    
    
                                                                
            
    
    
                                                                
            
    
    
                                                                
            
    
    
                                                                
            
    
    
                                                        
            
    
    
                                                        
            
    
    
                                                        
            
Post your comment